Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NovoCure Ltd Director's Dealing 2021

May 28, 2021

31949_dirs_2021-05-28_5bf768bc-3cca-46f5-bb63-78bd43fd37ce.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2021-05-27

Reporting Person: Benaim Ely (Chief Medical Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-05-27 Ordinary Shares M 1833 $47.56 Acquired 30887 Direct
2021-05-27 Ordinary Shares S 1833 $200 Disposed 29054 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-05-27 Options to Buy Ordinary Shares $47.56 M 1833 Disposed 2029-05-07 Ordinary Shares (1833.0) Direct

Footnotes

F1: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim.

F2: Fully vested as of the date hereof.